Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733990 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
A Phase 1 study, sponsored by Faron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
NCT03733990 is a Phase 1 study that has completed, run by Faron Pharmaceuticals. The registered enrollment target is 216 participants.
The verdict
NCT03733990, a Phase 1 study, has completed, sponsored by Faron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
Interventions
- BIOLOGICAL FP-1305 (bexmarilimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733990
The ClinicalTrials.gov registry entry for NCT03733990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Faron Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FP-1305 (bexmarilimab) is the first listed.
NCT03733990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733990 about?
NCT03733990 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)". This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates ...
What is the current status of trial NCT03733990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2018-12-03. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT03733990?
The interventions under investigation include: FP-1305 (bexmarilimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03733990?
This trial is sponsored by Faron Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.